Skip to main content
Supriya Lifescience Limited logo

Supriya Lifescience Limited — Investor Relations & Filings

Ticker · SUPRIYA ISIN · INE07RO01027 LEI · 894500RBVJX1EOJP0Y02 BSE.NS Manufacturing
Open in API
Filings indexed 475 across all filing types
Latest filing 2026-05-27 Investor Presentation
Country IN India
Listing BSE.NS SUPRIYA

About Supriya Lifescience Limited

https://www.supriyalifescience.com

Supriya Lifescience Limited is a research-driven manufacturer of Active Pharmaceutical Ingredients (APIs) with a focus on diverse therapeutic segments. The company specializes in the production of antihistamines, anti-allergics, vitamins, anesthetics, and anti-asthmatics. Its core product portfolio includes Chlorpheniramine Maleate, Ketamine Hydrochloride, and Salbutamol Sulphate, maintaining a significant global market share in these niche categories. Operating with a strong emphasis on backward integration, the firm ensures supply chain reliability and cost efficiency. The manufacturing infrastructure is compliant with international regulatory standards, including approvals from the USFDA, EDQM, and PMDA. Supriya Lifescience serves a broad international clientele across more than 100 countries, catering to both regulated and semi-regulated markets through its advanced R&D capabilities and commitment to quality excellence.

Recent filings

Filing Released Lang Actions
Investor Presentation enclosed herewith.
Investor Presentation Classification · 98% confidence The document is titled “Investor Presentation” and contains detailed slides, financial highlights (Q4 & FY26 P&L, balance sheet), business overview, strategy, and charts – exactly fitting the definition of an Investor Presentation. It is not merely an announcement of results, nor a call transcript or standalone report. Therefore, it is classified as IP (Investor Presentation).
2026-05-27 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is a slide deck titled “Q4FY26 Investor Presentation” addressed to stock exchanges, containing a Safe Harbour statement, financial highlights, P&L, balance sheet, business overview, strategy and operational details. It is clearly an investor presentation, not a formal regulatory filing like a 10-K or interim report, and is intended for investors to communicate financial results and strategy.
2026-05-27 English
Enclosed herewith announcement pertaining to Dividend declared by the Company at its Board Meeting
Audit Report / Information Classification · 84% confidence The document is a Regulation 30 (‘Outcome of Board Meeting’) filing to stock exchanges disclosing the Board’s approval of the audited financial results for the quarter and year ended March 31, 2026, accompanied by the Statutory Auditor’s report (unmodified opinion) on those standalone results. It contains the full audited financials and the auditor’s report, and is not a full annual report (10-K) nor a mere announcement of publication; instead it is the audit report and financial results submission under SEBI Listing Regulations. This corresponds to a standalone Audit Report / Information filing. FY 2026
2026-05-27 English
Audited Financial Results for quarter and year March 31, 2026.
Interim / Quarterly Report Classification · 72% confidence The document is a formal stock‐exchange filing under SEBI Regulation 30 detailing the Outcome of the Board Meeting held on May 27, 2026. It announces and encloses the Audited Financial Results for the quarter and year ended March 31, 2026, together with the Independent Auditor’s Report and a CFO declaration. It contains full standalone financial statements (detailed tables of revenues, expenses, profits, etc.) rather than just a brief highlight release. This is characteristic of a comprehensive periodic results report (in India the Q4 audited results often include both quarter and full‐year figures), fitting the Interim/Quarterly Report category. Thus, the correct classification is IR (Interim/Quarterly Report). FY 2026
2026-05-27 English
Dividend
Interim / Quarterly Report Classification · 85% confidence The document is the official outcome of a Board Meeting under SEBI LODR, providing the Audited Financial Results for the quarter and year ended March 31, 2026, together with the Statutory Auditor’s Report and detailed financial tables. It contains substantive financial statements (income, expenses, profit, etc.) and is not merely a summary or highlight release (ER), nor a full annual report (10-K), but rather a comprehensive results announcement for a period shorter than, and including, a quarter. Therefore, it best fits “Interim / Quarterly Report (IR).” FY 2026
2026-05-27 English
Outcome of the Board Meeting is enclosed herewith.
Interim / Quarterly Report Classification · 85% confidence The document is a formal board meeting outcome under SEBI Listing Regulations 2015 (Regulation 30) announcing the audited financial results for the quarter and year ended March 31, 2026. It includes the Independent Auditor’s Report and detailed standalone financial statements (actual numbers for quarterly and annual periods). This qualifies as an interim/quarterly report providing substantive financial data, not merely an earnings highlight or a report publication notice. Therefore, it is classified as an Interim / Quarterly Report (IR). FY 2026
2026-05-27 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.